FIELD: biochemistry.
SUBSTANCE: invention is related a pharmaceutical composition for use in the treatment of S. aureus infection. A method for treating an S. aureus infection in a patient, a method for reducing bacterial agglutination of S. aureus and/or the formation of a thromboembolic lesion in a patient, a method for delaying the onset of sepsis, a method for preventing or reducing the severity of sepsis associated with S. aureus using the specified composition are also disclosed.
EFFECT: invention has the ability to effectively treat S. aureus infection.
18 cl, 18 dwg, 5 tbl, 11 ex
Title | Year | Author | Number |
---|---|---|---|
COMBINATIONS OF ANTIBODIES TO STAPHYLOCOCCUS AUREUS | 2019 |
|
RU2804815C2 |
ANTIBODIES AGAINST STAPHYLOCOCCUS AUREUS LEUKOTOXINS | 2019 |
|
RU2805969C2 |
ANTIBODIES TO S. AUREUS SURFACE DETERMINANTS | 2013 |
|
RU2698131C2 |
STAPHYLOCOCCUS AUREUS CLUMPING FACTOR A (ClfA) ANTIBODY | 2019 |
|
RU2818805C2 |
BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
BISPECIFIC ANTIBODIES TO CCL2 | 2020 |
|
RU2819613C1 |
ADVANCED PROCOAGULANT ANTIBODIES | 2019 |
|
RU2810748C2 |
METHODS FOR DETECTING FOLATE RECEPTOR 1 IN PATIENT SAMPLE | 2018 |
|
RU2759410C2 |
ANTIBODIES BINDING TO GPRC5D | 2019 |
|
RU2797268C2 |
Authors
Dates
2023-11-21—Published
2013-11-06—Filed